Ilaris (canakinumab)

Ilaris (canakinumab)

General Description:
Ilaris (canakinumab) is a monoclonal antibody prescription medicine that targets interleukin-1β (IL-1β), a key cytokine involved in inflammation. It is indicated for the treatment of several autoinflammatory and inflammatory diseases, including:

• Periodic Fever Syndromes, such as:
  • Cryopyrin-Associated Periodic Syndromes (CAPS)
  • Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS)
  • Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD)
  • Familial Mediterranean Fever (FMF)
• Active Still’s Disease, including:
  • Adult-Onset Still’s Disease (AOSD)
  • Systemic Juvenile Idiopathic Arthritis (SJIA)
• Gout Flares

By neutralizing IL-1β, Ilaris helps control excessive inflammation, reduce flare frequency, and alleviate systemic symptoms associated with these chronic conditions.

---

Disease Indications:
Rheumatoid Arthritis and Other Autoinflammatory Disorders

---

Manufacturer:
Novartis Pharmaceuticals

---

Usage:
Intravenous

---

Medicine Approved by:
• European Medicines Agency (EMA)
• Food and Drug Administration (FDA)

---

Package:
• Single-use vial (varies by dose and indication)

---

Shipping:
Cold Chain Shipping
Ilaris contains temperature-sensitive biologic ingredients that can be degraded by heat, light, or improper handling. To maintain its stability and therapeutic integrity, it is transported using cold chain delivery, which employs specialized medical couriers with temperature-controlled packaging and vehicles.

Although cold chain shipping may incur higher costs than standard shipping, it ensures that Ilaris arrives uncompromised, safe, and fully effective for patient use.

---